Evaluation for efficacy and safety of Angiotensin Converting Enzyme Inhibitor in treatment of proteinuria in cyanotic congenital heart diseases

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180208003

Enrollment

100

Registered

2018-02-08

Start date

2018-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oxygen saturation urine protein serum creatinine enalapril&#44

Interventions

enalapril were given in group 1,placebo were given in arm 1

Active Comparator Drug,Placebo Comparator Drug

enalapril,placebo

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: cyanotic congenital heart diseases with microalbuminuria

Exclusion criteria

Exclusion criteria: Patients that have contraindicated for enalapril

Design outcomes

Primary

Measure	Time frame
proteinuria 0, 1, 3 month urine protein analysis	—

Secondary

Measure	Time frame
renal function 0, 1, 3 month serum Creatinine	—

Countries

Thailand

Contacts

Public ContactNattaphorn Hongsawong

Chiang Mai University Hospital

natyoke@yahoo.com0899519937

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026